. Author manuscript; available in PMC: 2014 Aug 14.

Published in final edited form as: J Am Acad Dermatol. 2008 Feb 4;58(4):625–631. doi: 10.1016/j.jaad.2007.12.035

Table 2.

Summary of Efficacy Endpoints at week 12^*

Efficacy Outcome	Results of subjects who completed trial (n=8)	Results of intention to treat analysis (n=12)^*
Response rate based on achieving at least a PGA of “good”	25%, 95% CI (3%, 65%)	16.7%, 95% CI (2%, 48%)
PGA at week 12 (median, IQR)	Unchanged-Slight improvement (Unchanged, Fair-Good)	Unchanged (Worse-Unchanged, Slight Improvement)
PASI 75 at week 12	25%, 95% CI (3%, 65%)	16.7%, 95% CI (2%, 48%)
Change in PASI (baseline-week 12) (median, IQR)	5.4 (0.65, 7.6) p= 0.04	0.65 (−1.25, 6.5) p=0.26
Change in Skindex^**(median, IQR)	0.35 (IQR −5.5, 5.0) p= 0.9	0.0 (−2.55, 4.95) p=0.63

data taken from latest visit and carried forward for subjects who withdrew.

^**

positive values indicate an increase in Skindex scores, suggesting a decrease in QOL